Inovio Clinical Trials: Infectious Disease

Inovio Biomedical or its partners/collaborators are conducting the following ongoing clinical trials for the treatment of infectious diseases. Patients are being recruited for these trials, with details available by following the links below.

Indications: HIV

Treatment: PENNVAX™-B HIV Therapeutic Vaccine (807682)

Study title: A Phase Ib Partially Randomized Pilot Study Intended to Evaluate the Safety and Immunological Effects of HIV-1 DNA Immunization (PENNVAX-B) With or Without Co-Administration of Constructs Containing DNA Encoding for the Expression of Either IL-12 or IL-15 in HIV Infected Individuals

Trial Stage: Phase I

http://www.clinicaltrials.gov/ct2/show/NCT00775424?term=pennvax&rank=1

Indications: HIV

Treatment: PENNVAX™-B HIV Preventative Vaccine (HVTN-080)

Study title: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX™-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in Healthy, HIV-1-Uninfected Adult Participants

Trial Stage: Phase I

http://www.clinicaltrials.gov/ct2/show/NCT00991354?term=NCT00991354&rank=1

Indications: HIV

Treatment: PENNVAX™-B HIV Preventative Vaccine (HVTN-070)

Study title: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Given Alone, With IL-12 DNA, or With a Dose Escalation of IL-15 DNA, in Healthy, HIV-1-Uninfected Adults Participants

Trial Stage: Phase I (study is ongoing, but not recruiting participants)